Innovative Cellular Therapeutics Holdings reports Lyell Immunopharma share sale worth $137PUBT·Jul 20 at 01:56 PMLYEL-0.15%
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Given Consensus Rating of "Moderate Buy" by BrokeragesMarket Beat·Jul 19 at 03:14 AMLYEL-0.15%
Innovative Cellular Therapeutics Holdings reports Lyell Immunopharma common share disposal worth $137.3PUBT·Jul 17 at 08:45 PMLYEL-0.15%
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga_article·Jul 6 at 07:05 AMUPC+2.04%LUCY-8.41%
Lyell Immunopharma initial beneficial ownership filing names Innovative Cellular Therapeutics Holdings as 10% ownerPUBT·Jun 18 at 03:07 PMLYEL-0.15%
Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress | LYEL Stock NewsStockTitan·Jun 12 at 03:45 AMLYEL-0.15%
Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion | LYEL Stock NewsStockTitan·Jun 7 at 09:00 PMLYEL-0.15%
Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 CongressUnusual Whales·Jun 4 at 03:06 PMLYEL-0.15%
Lyell Immunopharma, Inc. Stock 12‑Month Price Target Cut to $37.17, Implies 150% UpsideTradingView·Jun 3 at 09:20 AMLYEL-0.15%
Lyell Immunopharma Targets 2027 FDA Filing as CAR-T Pipeline AdvancesMarket Beat·May 27 at 03:03 AMLYEL-0.15%
